Precision BioSciences Doses First Patient in PBGENE-DMD Gene-Editing Trial

Company: Precision BioSciences · Asset: PBGENE-DMD · Platform: ARCUS Gene Editing · Indication: Duchenne Muscular Dystrophy · Date: August 24, 2026 Summary Precision BioSciences disclosed that the first participant received PBGENE-DMD in the Phase 1/2a FUNCTION-DMD trial. The program uses two ARCUS nucleases delivered in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Terremoto – $108M Series C Degrader Platform
Nurix–Roche BTK Degrader Deal Closes
Silence Therapeutics Prices Upsized $175 Million Offering After Positive Divesiran Data
Lilly + Ascidian – $1.9B RNA Exon Editing Deal